Wednesday, August 27, 2014

ABT-199 Trial

I started a clinical trial of ABT-199 3 weeks ago. (sorta technical Myeloma Beacon EHA 2013 Congress Abstract P210 (Poster Presentation)) It is in combination with Velcade and Dex. The Dex is being reduced thank you very much!

Three weeks on the protocol produced a 37% drop in my myeloma marker (Igg-Lambda Free Light Chains).

It was easy easy easy just time consuming. I like to view it as a behaviour disorder which compels me to drive almost an hour to an overpriced internet cafe'. I alway bring a book and laptop and don't bore easily so Life is good!

The disorder then morphs into the Dex Pirate from which all living creatures should beware.
I've been known to cry, laugh, explode and threaten all manor of pirate inspired tortures or gruesome methods of death.

Life is getting better. The first cycle of most clinical trials is usually very time consuming. I spent 3 days in the hospital being watched, a couple days in the clinic being blood tested. That's over as are the weekly doctors visits. Now it's just once every 3 week cycle and a couple Velcade shots and dear ol' Dex twice a week for the first 2 of the 3 week cycle.

Easy peasy! Scotty needs to get the transporter working again. I've been slacking off while in dry dock here in Florida.

Tuesday, June 24, 2014

Biannual Review

It is amazing to me that I can go 2 years without thinking about Laughing Plasma Cells. After the last post about my newly repaired arm I never went back to work. Instead I retired, moved to Amelia Island and am working on reinventing myself. As for the plumbers tape and drywall screws the repair was nothing short of amazing. Being a southpaw again has improved both my handwriting and my quality of life.

I just do the myeloma thing. It does do me on occasion but life is good. I did a few clinical trials, a few slightly less common combinations and all kinds of whacky stuff as well. I even got John of God involved.

After a little time off to clear the old chemicals out I'll try another clinical trial using an immune modulator,  second mitochondrial-derived activator of caspases (SMAC) mimetic LCL161. (Isn't cut and paste wonderful - I hope to never actually have to remember or say that outloud.) In short SMAC, although not related to heroine, is capable of screwing with cell death programming. When the smac be flowing my way I don't be caring no more.

On that note I leave this blog be for a few more years. Cheers